Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 1, 2011, Pages 25-37

  Mimeault, Murielle ^a   Batra, Surinder K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Akt; Chemopreventive treatments; Combination therapy; Dietary compounds; Metastases; Prostate cancer; Prostatic cancer stem progenitor cells; PTEN; Transgenic mouse models

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ANTIESTROGEN; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; APIGENIN; BAICALEIN; CELECOXIB; CURCUMIN; CYCLOPAMINE; DECORIN; DOCETAXEL; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; FINASTERIDE; FLURBIPROFEN; GENISTEIN; LYCOPENE; MITOXANTRONE; NEXRUTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; QUERCETIN; RESVERATROL; SELENIUM; SILIBININ; SULINDAC; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER MODEL; CANCER PREVENTION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL MIGRATION; CHEMOPROPHYLAXIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GENE ACTIVATION; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; ONCOGENES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REGENERATION;

ANIMALIA; ERINACEIDAE; MUS MUSCULUS;

EID: 79953072366     PISSN: 0304419X     EISSN: 0304419X     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.03.001     Document Type: Review

References (170)

1. Ashida S., Nakagawa H., Katagiri T., Furihata M., Iiizumi M., Anazawa Y., Tsunoda T., Takata R., Kasahara K., Miki T., Fujioka T., Shuin T., Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004, 64:5963-5972.
2. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003, 349:366-381.
3. Mimeault M., Batra S.K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006, 27:1-22.
4. Mimeault M., Mehta P.P., Hauke R., Batra S.K. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr. Rev. 2008, 29:234-252.
5. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
6. Yuan X., Balk S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 2009, 27:36-41.
7. Karlou M., Tzelepi V., Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat. Rev. Urol. 2010, 7:494-509.
8. Winquist E., Waldron T., Berry S., Ernst D.S., Hotte S., Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006, 6:112.
9. Ao M., Franco O.E., Park D., Raman D., Williams K., Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67:4244-4253.
10. Ellem S.J., Wang H., Poutanen M., Risbridger G.P. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am. J. Pathol. 2009, 175:1187-1199.
11. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998, 58:204-209.
12. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad. Sci. USA 1998, 95:5246-5250.
13. Verhagen P.C., van Duijn P.W., Hermans K.G., Looijenga L.H., van Gurp R.J., Stoop H., Van der Kwast T.H., Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J. Pathol. 2006, 208:699-707.
14. Meyers F.J., Gumerlock P.H., Chi S.G., Borchers H., Deitch A.D., deVere White R.W. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998, 83:2534-2539.
15. Heidenberg H.B., Sesterhenn I.A., Gaddipati J.P., Weghorst C.M., Buzard G.S., Moul J.W., Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 1995, 154:414-421.
16. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J., Kallioniemi O.P., Gelmann E.P. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000, 60:6111-6115.
17. De Marzo A.M., Meeker A.K., Epstein J.I., Coffey D.S. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 1998, 153:911-919.
18. Mimeault M., Moore E., Moniaux N., Henichart J.P., Depreux P., Lin M.F., Batra S.K. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int. J. Cancer 2006, 118:1022-1031.
19. Mimeault M., Johansson S.L., Venkatraman G., Moore E., Henichart J.P., Depreux P., Lin M.F., Batra S.K. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol. Cancer Ther. 2007, 6:967-978.
20. Mimeault M., Venkatraman G., Johansson S.L., Moore E., Henichart J.P., Depreux P., Lin M.F., Batra S.K. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int. J. Cancer 2007, 120:160-169.
21. Lorenzo Di, Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., D'Armiento M., De Laurentiis M., De Placido S., Catalano G., Bianco A.R., Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 2002, 8:3438-3444.
22. Schafer W., Funke P.J., Kunde D., Rausch U., Wennemuth G., Stutzer H. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations. J. Urol. 2006, 176:532-537.
23. Le Page C., Koumakpayi I.H., Lessard L., Mes-Masson A.M., Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005, 65:130-140.
24. Hammarsten P., Karalija A., Josefsson A., Rudolfsson S.H., Wikstrom P., Egevad L., Granfors T., Stattin P., Bergh A. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin. Cancer Res. 2010, 16:1245-1255.
25. Sheng T., Li C., Zhang X., Chi S., He N., Chen K., McCormick F., Gatalica Z., Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 2004, 3:29.
26. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M., Beachy P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
27. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62:1832-1837.
28. Ayala G., Thompson T., Yang G., Frolov A., Li R., Scardino P., Ohori M., Wheeler T., Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 2004, 10:6572-6578.
29. Shukla S., MacLennan G.T., Hartman D.J., Fu P., Resnick M.I., Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer 2007, 121:1424-1432.
30. Ross J.S., Kallakury B.V., Sheehan C.E., Fisher H.A., Kaufman R.P., Kaur P., Gray K., Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin. Cancer Res. 2004, 10:2466-2472.
31. Sweeney C., Li L., Shanmugam R., Bhat-Nakshatri P., Jayaprakasan V., Baldridge L.A., Gardner T., Smith M., Nakshatri H., Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004, 10:5501-5507.
32. Koumakpayi I.H., Le Page C., Mes-Masson A.M., Saad F. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br. J. Cancer 2010, 102:1163-1173.
33. Wang J., Cai Y., Ren C., Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006, 66:8347-8351.
34. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
35. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., Cao X., Wei J.T., Rubin M.A., Shah R.B., Chinnaiyan A.M. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006, 66:3396-3400.
36. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
37. Datta M.W., Hernandez A.M., Schlicht M.J., Kahler A.J., DeGueme A.M., Dhir R., Shah R.B., Farach-Carson C., Barrett A., Datta S. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol. Cancer 2006, 5:9.
38. Chung L.W., Baseman A., Assikis V., Zhau H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol. 2005, 173:10-20.
39. Zhao H., Peehl D.M. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate 2009, 69:991-1000.
40. Maitland N.J., Bryce S.D., Stower M.J., Collins A.T. Prostate cancer stem cells: a target for new therapies. Ernst Schering Found. Symp. Proc. 2006, 5:155-179.
41. Kasper S., Cookson M.S. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol. Clin. North Am. 2006, 33:201-210.
42. Mimeault M., Hauke R., Mehta P.P., Batra S.K. Recent advances on cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Mol. Cell. Med. 2007, 11:981-1011.
43. Miki J., Furusato B., Li H., Gu Y., Takahashi H., Egawa S., Sesterhenn I.A., McLeod D.G., Srivastava S., Rhim J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007, 67:3153-3161.
44. Brown M.D., Gilmore P.E., Hart C.A., Samuel J.D., Ramani V.A., George N.J., Clarke N.W. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007, 67:1384-1396.
45. Zenzmaier C., Untergasser G., Berger P. Aging of the prostate epithelial stem/progenitor cell. Exp. Gerontol. 2008, 43:981-985.
46. Gu G., Yuan J., Wills M., Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007, 67:4807-4815.
47. Rowehl R.A., Crawford H., Dufour A., Ju J., Botchkina G.I. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 2008, 5:301-310.
48. Li T., Su Y., Mei Y., Leng Q., Leng B., Liu Z., Stass S.A., Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest. 2009, 30:234-244.
49. Guzman-Ramirez N., Voller M., Wetterwald A., Germann M., Cross N.A., Rentsch C.A., Schalken J., Thalmann G.N., Cecchini M.G. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009, 69:1683-1693.
50. van den Hoogen C., van der Horst G., Cheung H., Buijs J.T., Lippitt J.M., Guzman-Ramirez N., Hamdy F.C., Eaton C.L., Thalmann G.N., Cecchini M.G., Pelger R.C., van der Pluijm G. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 2010, 70:5163-5173.
51. Man Y.G., Gardner W.A. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Med. Hypotheses 2007, 70:387-408.
52. Bui M., Reiter R.E. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev. 1998, 17:391-399.
53. Liu T., Xu F., Du X., Lai D., Liu T., Zhao Y., Huang Q., Jiang L., Huang W., Cheng W., Liu Z. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol. Cell. Biochem. 2010, 340:265-273.
54. Fan X., Liu S., Su F., Pan Q., Lin T. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol. Oncol. 2010.
55. Mimeault M., Johansson S.L., Henichart J.P., Depreux P., Batra S.K. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and non-side population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther. 2010, 9:617-630.
56. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
57. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 1995, 92:3439-3443.
58. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., Angelopoulou R., Rosen J.M., Greenberg N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56:4096-4102.
59. Johnson M.A., Iversen P., Schwier P., Corn A.L., Sandusky G., Graff J., Neubauer B.L. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate 2005, 62:322-338.
60. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221.
61. Wang S., Garcia A.J., Wu M., Lawson D.A., Witte O.N., Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl Acad. Sci. USA 2006, 103:1480-1485.
62. Song H., Zhang B., Watson M.A., Humphrey P.A., Lim H., Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28:3307-3319.
63. Rizzo S., Attard G., Hudson D.L. Prostate epithelial stem cells. Cell Prolif. 2005, 38:363-374.
64. Blum R., Gupta R., Burger P.E., Ontiveros C.S., Salm S.N., Xiong X., Kamb A., Wesche H., Marshall L., Cutler G., Wang X., Zavadil J., Moscatelli D., Wilson E.L. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS ONE 2009, 4:e5722.
65. Trerotola M., Rathore S., Goel H.L., Li J., Alberti S., Piantelli M., Adams D., Jiang Z., Languino L.R. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am. J. Transl. Res. 2010, 2:135-144.
66. Leong K.G., Wang B.E., Johnson L., Gao W.Q. Generation of a prostate from a single adult stem cell. Nature 2008, 456:804-808.
67. Chen B.Y., Liu J.Y., Chang H.H., Chang C.P., Lo W.Y., Kuo W.H., Yang C.R., Lin D.P. Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem. Biophys. Res. Commun. 2007, 357:1084-1089.
68. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
69. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
70. Mimeault M., Batra S.K. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res. Rev. 2009, 8:94-112.
71. Duhagon M.A., Hurt E.M., Sotelo-Silveira J.R., Zhang X., Farrar W.L. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 2010, 11:324.
72. Klarmann G.J., Hurt E.M., Mathews L.A., Zhang X., Duhagon M.A., Mistree T., Thomas S.B., Farrar W.L. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 2009, 26:433-446.
73. Kong D., Banerjee S., Ahmad A., Li Y., Wang Z., Sethi S., Sarkar F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 2010, 5:e12445.
74. Bae K.M., Su Z., Frye C., McClellan S., Allan R.W., Andrejewski J.T., Kelley V., Jorgensen M., Steindler D.A., Vieweg J., Siemann D.W. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J. Urol. 2010, 183:2045-2053.
75. Acharya A., Das I., Chandhok D., Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell Longev. 2010, 3:23-34.
76. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., Berry P.A., Hyde C.F., Lewis J.L., Stower M.J., Maitland N.J., Collins A.T. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9:R83.
77. Mathews L.A., Hurt E.M., Zhang X., Farrar W.L. Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol. Cancer 2010, 9:267.
78. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J.G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
79. Tang D.G., Patrawala L., Calhoun T., Bhatia B., Choy G., Schneider-Broussard R., Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog. 2007, 46:1-14.
80. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67:6796-6805.
81. Li H., Chen X., Calhoun-Davis T., Claypool K., Tang D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 2008, 68:1820-1825.
82. Wei C., Guomin W., Yujun L., Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?. Cancer Biol. Ther. 2007, 6:763-768.
83. Chauchereau A., Al Nakouzi N., Gaudin C., Le Moulec S., Compagno D., Auger N., Benard J., Opolon P., Rozet F., Validire P., Fromont G., Fizazi K. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp. Cell Res. 2011, 317:262-275.
84. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
85. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a pro-inflammatory signature leading to EMT and stemness. Antioxid. Redox. Signal. 2011.
86. Xin L., Lawson D.A., Witte O.N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl Acad. Sci. USA 2005, 102:6942-6947.
87. Lawson D.A., Zong Y., Memarzadeh S., Xin L., Huang J., Witte O.N. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl Acad. Sci. USA 2010, 107:2610-2615.
88. Goodyear S.M., Amatangelo M.D., Stearns M.E. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate 2009, 69:689-698.
89. Chen B.Y., Lin D.P., Liu J.Y., Chang H., Huang P.H., Chen Y.L., Chang H.H. A mouse prostate cancer model induced by Hedgehog overexpression. J. Biomed. Sci. 2006, 13:373-384.
90. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997, 57:4687-4691.
91. Gingrich J.R., Barrios R.J., Foster B.A., Greenberg N.M. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 1999, 2:70-75.
92. Yan Y., Sheppard P.C., Kasper S., Lin L., Hoare S., Kapoor A., Dodd J.G., Duckworth M.L., Matusik R.J. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 1997, 32:129-139.
93. Zhang J., Thomas T.Z., Kasper S., Matusik R.J. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000, 141:4698-4710.
94. Zhang J., Gao N., Kasper S., Reid K., Nelson C., Matusik R.J. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology 2004, 145:134-148.
95. Luchman H.A., Benediktsson H., Villemaire M.L., Peterson A.C., Jirik F.R. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS ONE 2008, 3:e3940.
96. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 2001, 101:61-69.
97. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl Acad. Sci. USA 2001, 98:11563-11568.
98. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R.M., Tsukamoto T., Shappell S.B., Matusik R.J. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 2001, 61:2239-2249.
99. Calvo A., Perez-Stable C., Segura V., Catena R., Guruceaga E., Nguewa P., Blanco D., Parada L., Reiner T., Green J.E. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer. Prostate 2010, 70:630-645.
100. Casimiro M., Rodriguez O., Pootrakul L., Aventian M., Lushina N., Cromelin C., Ferzli G., Johnson K., Fricke S., Diba F., Kallakury B., Ohanyerenwa C., Chen M., Ostrowski M., Hung M.C., Rabbani S.A., Datar R., Cote R., Pestell R., Albanese C. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 2007, 67:4364-4372.
101. Rodriguez O.C., Lai E.W., Vissapragada S., Cromelin C., Avetian M., Salinas P., Ramos H., Kallakury B., Casimiro M., Lisanti M.P., Tanowitz H.B., Pacak K., Glazer R.I., Avantaggiati M., Albanese C. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am. J. Pathol. 2009, 174:2051-2060.
102. Fricke S.T., Rodriguez O., Vanmeter J., Dettin L.E., Casimiro M., Chien C.D., Newell T., Johnson K., Ileva L., Ojeifo J., Johnson M.D., Albanese C. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006, 66:708-717.
103. Rouet V., Bogorad R.L., Kayser C., Kessal K., Genestie C., Bardier A., Grattan D.R., Kelder B., Kopchick J.J., Kelly P.A., Goffin V. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc. Natl Acad. Sci. USA 2010, 107:15199-15204.
104. Li Z., Szabolcs M., Terwilliger J.D., Efstratiadis A. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006, 27:1054-1067.
105. Zhong C., Saribekyan G., Liao C.P., Cohen M.B., Roy-Burman P. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res. 2006, 66:2188-2194.
106. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
107. Pearson H.B., Phesse T.J., Clarke A.R. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 2009, 69:94-101.
108. Liu Y., Mo J.Q., Hu Q., Boivin G., Levin L., Lu S., Yang D., Dong Z., Lu S. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res. 2008, 68:6396-6406.
109. Iwata T., Schultz D., Hicks J., Hubbard G.K., Mutton L.N., Lotan T.L., Bethel C., Lotz M.T., Yegnasubramanian S., Nelson W.G., Dang C.V., Xu M., Anele U., Koh C.M., Bieberich C.J., De Marzo A.M. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS. ONE 2010, 5:e9427.
110. Nandana S., Ellwood-Yen K., Sawyers C., Wills M., Weidow B., Case T., Vasioukhin V., Matusik R. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate 2010, 70:591-600.
111. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P.W., Golub T.R., Loda M., Sellers W.R. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl Acad. Sci. USA 2003, 100:7841-7846.
112. Lee S.H., Poulogiannis G., Pyne S., Jia S., Zou L., Signoretti S., Loda M., Cantley L.C., Roberts T.M. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc. Natl Acad. Sci. USA 2010, 107:11002-11007.
113. Kim J., Eltoum I.E., Roh M., Wang J., Abdulkadir S.A. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 2009, 5:e1000542.
114. Peduto L., Reuter V.E., Sehara-Fujisawa A., Shaffer D.R., Scher H.I., Blobel C.P. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 2006, 25:5462-5466.
115. Wang J., Eltoum I.E., Lamartiniere C.A. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol. Cell. Endocrinol. 2004, 219:171-180.
116. Shukla S., MacLennan G.T., Marengo S.R., Resnick M.I., Gupta S. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64:224-239.
117. Mack J.T., Helke K.L., Normand G., Green C., Townsend D.M., Tew K.D. ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration. Cancer Lett. 2010, 300:154-161.
118. Zhang Z.X., Xu Q.Q., Huang X.B., Zhu J.C., Wang X.F. Early and delayed castrations confer a similar survival advantage in TRAMP mice. Asian J. Androl. 2009, 11:291-297.
119. Tang Y., Hamburger A.W., Wang L., Khan M.A., Hussain A. Androgen deprivation and stem cell markers in prostate cancers. Int. J. Clin. Exp. Pathol. 2009, 3:128-138.
120. Tang Y., Wang L., Goloubeva O., Khan M.A., Zhang B., Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin. Cancer Res. 2008, 14:2936-2943.
121. Qi J., Nakayama K., Cardiff R.D., Borowsky A.D., Kaul K., Williams R., Krajewski S., Mercola D., Carpenter P.M., Bowtell D., Ronai Z.A. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010, 18:23-38.
122. Qi J., Ronai Z.A. The Siah2-HIF-FoxA2 axis in prostate cancer-new markers and therapeutic opportunities. Oncotarget 2010, 1:379-385.
123. Tang Y., Wang L., Goloubeva O., Khan M.A., Lee D., Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate 2009, 69:1763-1773.
124. Chiaverotti T., Couto S.S., Donjacour A., Mao J.H., Nagase H., Cardiff R.D., Cunha G.R., Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 2008, 172:236-246.
125. Perez-Stable C., Altman N.H., Brown J., Harbison M., Cray C., Roos B.A. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab. Invest. 1996, 74:363-373.
126. Perez-Stable C., Altman N.H., Mehta P.P., Deftos L.J., Roos B.A. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 1997, 57:900-906.
127. Perez-Stable C.M., Schwartz G.G., Farinas A., Finegold M., Binderup L., Howard G.A., Roos B.A. The G gamma/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol. Biomark. Prev. 2002, 11:555-563.
128. Reiner T., de Las P.A., Parrondo R., Perez-Stable C. Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Mol. Cancer Res. 2007, 5:1171-1179.
129. Kasper S. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J. Cell. Biochem. 2005, 94:279-297.
130. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 1999, 96:1563-1568.
131. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 2001, 27:222-224.
132. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS. Biol. 2003, 1:E59.
133. Blando J., Portis M., Benavides F., Alexander A., Mills G., Dave B., Conti C.J., Kim J., Walker C.L. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am. J. Pathol. 2009, 174:1869-1879.
134. Mulholland D.J., Xin L., Morim A., Lawson D., Witte O., Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009, 69:8555-8562.
135. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., Cunha G.R., Cardiff R.D., Shen M.M., Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 2002, 62:2999-3004.
136. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abatex-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl Acad. Sci. USA 2002, 99:2884-2889.
137. Gao H., Ouyang X., Banach-Petrosky W., Borowsky A.D., Lin Y., Kim M., Lee H., Shih W.J., Cardiff R.D., Shen M.M., Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl Acad. Sci. USA 2004, 101:17204-17209.
138. Abdulkadir S.A., Magee J.A., Peters T.J., Kaleem Z., Naughton C.K., Humphrey P.A., Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell Biol. 2002, 22:1495-1503.
139. Gary B., Azuero R., Mohanty G.S., Bell W.C., Eltoum I.E., Abdulkadir S.A. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am. J. Pathol. 2004, 164:1607-1614.
140. Thomsen M.K., Ambroisine L., Wynn S., Cheah K.S., Foster C.S., Fisher G., Berney D.M., Moller H., Reuter V.E., Scardino P., Cuzick J., Ragavan N., Singh P.B., Martin F.L., Butler C.M., Cooper C.S., Swain A. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010, 70:979-987.
141. Abate-Shen C., Banach-Petrosky W.A., Sun X., Economides K.D., Desai N., Gregg J.P., Borowsky A.D., Cardiff R.D., Shen M.M. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003, 63:3886-3890.
142. Banach-Petrosky W., Jessen W.J., Ouyang X., Gao H., Rao J., Quinn J., Aronow B.J., Abate-Shen C. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 2007, 67:9089-9096.
143. Couto S.S., Cao M., Duarte P.C., Banach-Petrosky W., Wang S., Romanienko P., Wu H., Cardiff R.D., Abate-Shen C., Cunha G.R. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 2009, 77:103-111.
144. Elgavish A., Wood P.A., Pinkert C.A., Eltoum I.E., Cartee T., Wilbanks J., Mentor-Marcel R., Tian L., Scroggins S.E. Transgenic mouse with human mutant p53 expression in the prostate epithelium. Prostate 2004, 61:26-34.
145. Abou-Kheir W.G., Hynes P.G., Martin P.L., Pierce R., Kelly K. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten(-/-)TP53(-/-) prostate cancer model. Stem Cells 2010, 28:2129-2140.
146. Zhou Z., Flesken-Nikitin A., Corney D.C., Wang W., Goodrich D.W., Roy-Burman P., Nikitin A.Y. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006, 66:7889-7898.
147. Wang Y., Sudilovsky D., Zhang B., Haughney P.C., Rosen M.A., Wu D.S., Cunha T.J., Dahiya R., Cunha G.R., Hayward S.W. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res. 2001, 61:6064-6072.
148. Poutahidis T., Rao V.P., Olipitz W., Taylor C.L., Jackson E.A., Levkovich T., Lee C.W., Fox J.G., Ge Z., Erdman S.E. CD4+ lymphocytes modulate prostate cancer progression in mice. Int. J. Cancer 2009, 125:868-878.
149. Bruxvoort K.J., Charbonneau H.M., Giambernardi T.A., Goolsby J.C., Qian C.N., Zylstra C.R., Robinson D.R., Roy-Burman P., Shaw A.K., Buckner-Berghuis B.D., Sigler R.E., Resau J.H., Sullivan R., Bushman W., Williams B.O. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res. 2007, 67:2490-2496.
150. Lieberman R. Evolving strategies for prostate cancer chemoprevention trials. World J. Urol. 2003, 21:3-8.
151. Singh R.P., Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer 2006, 13:751-778.
152. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65:6934-6942.
153. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 2006, 66:4816-4825.
154. Khor T.O., Yu S., Barve A., Hao X., Hong J.L., Lin W., Foster B., Huang M.T., Newmark H.L., Kong A.N. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009, 69:7096-7102.
155. Zhang Y., Zhang J., Wang L., Quealy E., Gary B.D., Reynolds R.C., Piazza G.A., Lu J. A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev. Res. (Phila) 2010, 3:885-895.
156. Konijeti R., Henning S., Moro A., Sheikh A., Elashoff D., Shapiro A., Ku M., Said J.W., Heber D., Cohen P., Aronson W.J. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate 2010, 70:1547-1554.
157. Ghosh R., Graham H., Rivas P., Tan X.J., Crosby K., Bhaskaran S., Schoolfield J., Banu J., Fernandes G., Yeh I.T., Kumar A.P. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res. 2010, 30:857-865.
158. Agarwal R., Agarwal C., Ichikawa H., Singh R.P., Aggarwal B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 2006, 26:4457-4498.
159. Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., Macdonald R.S., Besch-Williford C.L., Lubahn D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010, 70:3382-3390.
160. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 2009, 125:1-8.
161. Hu Y., Sun H., Owens R.T., Wu J., Chen Y.Q., Berquin I.M., Perry D., O'Flaherty J.T., Edwards I.J. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 2009, 11:1042-1053.
162. Sarkar F.H., Li Y., Wang Z., Kong D. Novel targets for prostate cancer chemoprevention. Endocr. Relat. Cancer 2010, 17:R195-R212.
163. Flaig T.W., Su L.J., Harrison G., Agarwal R., Glode L.M. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int. J. Cancer 2007, 120:2028-2033.
164. Kawasaki B.T., Hurt E.M., Mistree T., Farrar W.L. Targeting cancer stem cells with phytochemicals. Mol. Interv. 2008, 8:174-184.
165. Handorean A.M., Yang K., Robbins E.W., Flaig T.W., Iczkowski K.A. Silibinin suppresses CD44 expression in prostate cancer cells. Am. J. Transl. Res. 2009, 1:80-86.
166. Raina K., Rajamanickam S., Singh R.P., Deep G., Chittezhath M., Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008, 68:6822-6830.
167. Kawasaki B.T., Hurt E.M., Kalathur M., Duhagon M.A., Milner J.A., Kim Y.S., Farrar W.L. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 2009, 69:827-837.
168. Volate S.R., Kawasaki B.T., Hurt E.M., Milner J.A., Kim Y.S., White J., Farrar W.L. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol. Cancer Ther. 2010, 9:461-470.
169. Kallifatidis G., Labsch S., Rausch V., Mattern J., Gladkich J., Moldenhauer G., Buchler M.W., Salnikov A.V., Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. 2011, 19:188-195.
170. Zhou Z., Flesken-Nikitin A., Nikitin A.Y. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res. 2007, 67:5683-5690.